TMED2

Across TCGA pan-cancer cohorts, TMED2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMED2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMED2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMED2 expression acts as an unfavorable survival marker.

BLCA, SARC, and CESC are the cancer types where TMED2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.178	0.627	.004	18	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
CESC	OS	Median	All	0.449	0.800	.013	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMED2–BLCA (DFS)

Open the BLCA breakdown →